A phase Ib study of porustobart (HBM4003), an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with hepatocellular carcinoma. The impact of anti-EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results